Defendant

Lannett Holdings, Inc.

5 cases as defendant.

Cases
5
Active
0
5 closed
Filed
2015
Top venue
D. New Jersey
3 cases

Company profile

Lannett Holdings, Inc. — the litigation-tracking name for Lannett Company, Inc. (NYSE: LCI until its delisting), a U.S. generic-drug manufacturer founded in 1942 as a Pennsylvania corporation and reincorporated in Delaware in 1991. Headquarters: Trevose, Pennsylvania (formerly Philadelphia). Lannett filed for Chapter 11 in 2023 and emerged under the seller entity Lannett Seller Holdco, Inc.; on June 29, 2026, Aurobindo Pharma USA Inc. (subsidiary of India's Aurobindo Pharma Limited) closed its acquisition of 100% of Lannett Company LLC for an enterprise value of about $250 million. Lannett is therefore now a private subsidiary of Aurobindo, not an independent public company.

Operations. Lannett develops, manufactures, packages and markets generic finished dosage forms — tablets, capsules, extended-release oral solids, topical, nasal and oral solutions — across roughly 100 product families, sold to wholesalers, distributors, chain pharmacies, mail-order pharmacies and government buyers. Its portfolio emphasizes non-opioid DEA-controlled substances, particularly ADHD therapeutics (e.g., amphetamine IR tablets, methylphenidate ER), generic liquids, and products such as levothyroxine, fluphenazine, posaconazole and sumatriptan, plus its NDA product Numbrino (cocaine hydrochloride nasal solution). Manufacturing is centered on a 425,000 sq ft cGMP plant in Seymour, Indiana, with capacity of about 3.6 billion doses annually. Reported net sales were $340.6 million in fiscal 2022 and about $306 million for the twelve months ended March 2025.

Litigation posture. Lannett is an operating company appearing exclusively as a defendant (0 plaintiff, 5 defendant entries) in U.S. patent litigation — the classic Hatch-Waxman ANDA-defendant profile, not an NPE. All tracked matters are venued in the District of New Jersey, a common forum for Paragraph IV pharmaceutical disputes, not a plaintiff-friendly NPE venue such as the Eastern District of Texas.

Notable cases. All five tracked records are Celgene Corporation v. Lannett Holdings, Inc., filed January 30, 2015 in D.N.J. (2:15-cv-00697) — evidently one action recorded multiple times. The suit followed Lannett's Paragraph IV ANDA for generic Thalomid (thalidomide); Lannett filed antitrust counterclaims, and the parties settled in October 2017 under a license permitting generic thalidomide launch on August 1, 2019.

Sources: lannett.com; Lannett FY2022 annual report/10-K; Aurobindo Pharma BSE disclosures (July 30, 2025; June 2026); Honigman press release; FiercePharma; CourtListener/Cigna complaint (D.N.J. 2:21-cv-00090).

Celgene Corporation v. Lannett Holdings, Inc.

settled
Docket:
2:15-cv-00697
Filed:
2015-01-30

Celgene filed an ANDA patent infringement action against Lannett over generic thalidomide (Lannett ANDA No. 206601), asserting fifteen patents. The parties settled in 2017, with Lannett converting its Paragraph IV certification on the '745 patent to a Paragraph III certification and receiving a license to market generic thalidomide as of August 1, 2019. The narrative could not confirm that U.S. 7,959,566 was among the fifteen asserted patents.

Celgene Corporation v. Lannett Holdings, Inc.

unconfirmed
Docket:
2:15-cv-00697
Filed:
2015-01-30

Celgene's Hatch-Waxman ANDA suit against Lannett Holdings, filed in D.N.J. The narrative lists it among verified litigation naming US 6,869,399, and notes that the Barr and Lannett suits asserted a bundle of Celgene thalidomide patents including '501, '720, '977, and '784. The outcome on the '399 patent is unconfirmed.

Celgene Corporation v. Lannett Holdings, Inc.

settled
Docket:
2:15-cv-00697-SDW-SCM
Filed:
2015-01-30
Terminated:
2017-10-30
Patents:7141018

Celgene's ANDA/paragraph IV case against Lannett over generic thalidomide, in which Celgene asserted fifteen patents. The narrative could not confirm that '018 was among the asserted patents, although it was among Celgene's Orange Book-listed Thalomid patents. The case settled in October 2017 with a license permitting generic entry as of August 1, 2019.